Key Takeaways
- CRSP declined by as much as 11.59% during Friday’s session, reaching an intraday low of $51.21
- First quarter results disappointed: EPS of -$1.37 versus -$1.15 forecast; revenue of $0.86M compared to $4.72M projection — a 97.8% year-over-year decline
- Regeneron received approval for Otarmeni, a gene therapy that will be provided at no cost to qualifying U.S. patients, creating pricing pressure concerns for Casgevy
- CEO Samarth Kulkarni divested 10,349 shares on March 16; company insiders have collectively sold 51,828 shares in the last three months
- Wall Street consensus remains “Moderate Buy” with a mean price target of $64.53
CRISPR Therapeutics ($CRSP) experienced a turbulent Friday session. Shares plummeted by as much as 11.59%, touching $51.21 during intraday trading, before closing near $51.04 — a significant decline from the previous close of $55.18. Trading volume registered approximately 1.36 million shares, running about 27% lighter than typical daily activity.
The sharp decline stemmed from a combination of disappointing financial results and emerging competitive challenges from Regeneron.
Regarding quarterly performance, CRISPR posted earnings per share of -$1.37, falling short of the analyst consensus of -$1.15. Revenue registered merely $0.86 million — dramatically below the anticipated $4.72 million. This represents a staggering 97.8% contraction compared to the same period last year, shocking market participants.
The biotechnology firm’s return on equity remains deeply negative at -26.31%, accompanied by a substantially negative net margin. Wall Street forecasts indicate an expected full-year EPS of -$4.93.
Regeneron’s Complimentary Gene Therapy Creates Market Uncertainty
Compounding the earnings disappointment is news from Regeneron. The pharmaceutical giant secured regulatory approval for Otarmeni, a gene therapy it intends to provide at zero cost to qualifying U.S. patients. This strategic move represents a significant challenge to the gene-editing industry.
CRISPR’s lead product, Casgevy — co-developed with Vertex Pharmaceuticals — commands a list price of $2.2 million. Market participants worry that Regeneron’s no-cost strategy could trigger industry-wide pricing discussions, potentially undermining the value proposition of high-priced, single-administration treatments.
Casgevy achieved historic recognition as the first CRISPR-based treatment to receive FDA authorization, marking a groundbreaking achievement. However, commercial adoption has lagged expectations, and Regeneron’s announcement introduces additional uncertainty regarding future revenue generation.
Executive Stock Sales Compound Investor Concerns
Recent insider transactions have contributed to negative sentiment. CEO Samarth Kulkarni divested 10,349 shares on March 16 at an average price of $48.26, trimming his ownership position by approximately 4%. General Counsel James Kasinger offloaded 3,450 shares during the same timeframe.
During the previous three months, company insiders have collectively sold 51,828 shares valued at roughly $2.58 million. Current insider ownership stands at 4.30% of outstanding shares.
While such selling patterns aren’t uncommon among biotech executives managing stock-based compensation, the timing amplifies existing investor caution surrounding the stock.
Analyst perspectives remain somewhat divided but generally optimistic. Bank of America maintains a Buy recommendation with an $89 price objective. Needham holds a Buy rating targeting $82. TD Cowen assigns a Hold rating with a $45 target. Citizens JMP rates the stock Market Outperform with an $80 projection. The overall Street consensus registers as Moderate Buy, with an average price target of $64.53 — representing substantial upside from current trading levels.
The equity’s 50-day moving average sits at $52.68 while the 200-day moving average rests at $55.70. Market capitalization currently stands near $4.90 billion with a beta coefficient of 1.80.
Current price action shows CRSP trading around $51, positioned beneath both critical moving average levels.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
